myelodysplastic syndromes (MDS) | Page 15 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Author(s): 
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S
Primary Author: 
Montalban-Bravo G
Journal Title: 
Leukemia
Original Publication Date: 
Oct 2016

Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a

Bone Marrow Diseases: 

BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

Author(s): 
Lazarini M, Machado-Neto JA, Duarte AD, Pericole FV, Vieira KP, Niemann FS, Alvarez M, Traina F, Saad ST
Primary Author: 
Lazarini M
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2016

mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">No abstract available.

Bone Marrow Diseases: 

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

Author(s): 
Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR; from the Center for International Blood and Marrow Trans
Primary Author: 
Artz AS
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2016

We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and

Bone Marrow Diseases: 

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Author(s): 
Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Leukemia
Original Publication Date: 
Nov 2016

The Revised

Bone Marrow Diseases: 

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

Author(s): 
Lian XY, Zhang ZH, Deng ZQ, He PF, Yao DM, Xu ZJ, Wen XM, Yang L, Lin J, Qian J
Primary Author: 
Lian XY
Journal Title: 
PLoS One
Original Publication Date: 
Nov 2016

BACKGROUND:

Bone Marrow Diseases: 

My MDS Diagnosis and Progression of Treatment

Person's Name: 
Donna Adams

I am 66 years old. I grew up in Massachusetts and New Hampshire, where most of my family still lives. I have been retired from the federal government for 6 years. My husband Jack and I moved to Pennsylvania from Northern Virginia when we both retired. My husband and I have 3 children and 4 grandkids. Jack's kids reside in Virginia and my son lives in Massachusetts.

Content source: 
Bone Marrow Diseases: 

Find Out More:

Auburndale March for Marrow Walk

Get involved and give back by joining the 1st Annual Auburndale March for Marrow Walk!  Register now!

The event will be held on Saturday, February 18, 2017 at Lake Myrtle Sports Complex in Auburndale, FL. The walk will begin at 11:00 am, with registration/check-in beginning at 10:00 am.

Event Date: 
Sat, 02/18/2017 -
10:00am to 2:00pm
Community Event Type: